Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXCrescita TherapeuticsC$0.49C$0.52C$0.45▼C$0.69C$8.93M1.6915,150 shsN/A10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXCrescita Therapeutics0.00%-1.02%-8.49%-13.39%-8.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTXCrescita TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXCrescita Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXCrescita TherapeuticsC$16.62M0.54C$0.40 per share1.20C$0.83 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXCrescita Therapeutics-C$2.61M-C$0.15N/A∞N/A-15.73%-15.60%-8.26%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTXCrescita TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXCrescita Therapeutics5.772.702.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXCrescita TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCTXCrescita Therapeutics10.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXCrescita Therapeutics6218.41 millionN/ANot OptionableDEST, ANIC, and CTX HeadlinesRecent News About These CompaniesCrescita Therapeutics Inc. (CTX.TO) - Yahoo FinanceJune 26, 2025 | nz.finance.yahoo.comCrescita Therapeutics First Quarter 2025 Earnings: CA$0.049 loss per share (vs CA$0.032 loss in 1Q 2024)May 16, 2025 | finance.yahoo.comCrescita Reports First Quarter 2025 ResultsMay 14, 2025 | financialpost.comFCrescita Reports First Quarter 2025 ResultsMay 14, 2025 | financialpost.comFCrescita Reports Q4 and Fiscal 2024 ResultsMarch 18, 2025 | joplinglobe.comJInsider Buying: Crescita Therapeutics Inc. (TSE:CTX) Director Buys 86,000 Shares of StockDecember 29, 2024 | insidertrades.comCrescita Therapeutics Inc. (CRRTF)November 24, 2024 | finance.yahoo.comChordia Therapeutics Advances Cancer Drug DevelopmentNovember 20, 2024 | markets.businessinsider.comPromising Phase 1 Results of Compass Therapeutics’ CTX-471 Highlight Potential for Advanced Solid Tumors TreatmentNovember 11, 2024 | markets.businessinsider.comCompass Therapeutics presents biomarker data related to CTX-471November 8, 2024 | markets.businessinsider.comCrescita Reports Third Quarter 2024 ResultsNovember 6, 2024 | joplinglobe.comJCrescita Therapeutics Announces Approval of Normal Course Issuer BidSeptember 24, 2024 | businesswire.comKeynotes and 50 Companies to Present at the Planet MicroCap Showcase: VANCOUVER in ...September 24, 2024 | goldseiten.deCrescita Therapeutics Inc. Reports Second Quarter 2024 ResultsAugust 7, 2024 | finanznachrichten.deCrescita Reports Second Quarter 2024 ResultsAugust 7, 2024 | financialpost.comFBuy Rating Affirmed on Compass Therapeutics as Clinical Trials of CTX-009 Show Promise in Biliary Tract Cancer TreatmentAugust 6, 2024 | markets.businessinsider.comClosing Bell: Crescita Therapeutics Inc up on Monday (CTX)July 31, 2024 | theglobeandmail.comCrescita secures four-year term contract manufacturing revenue from largest CMO clientJuly 22, 2024 | msn.comCrescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 YearsJuly 22, 2024 | finance.yahoo.comCrescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery DeviceJuly 19, 2024 | valdostadailytimes.comVDEST, ANIC, and CTX Company DescriptionsCrescita Therapeutics TSE:CTXC$0.48 0.00 (0.00%) As of 07/3/2025Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
